All studies conducted in the CRU must be approved by the CRU Protocol Review Committee (CRU PRC). Each protocol must include a safety plan that is reviewed by the Research Safety Committee. If this committee recommends approval of the safety plan, the protocol is then reviewed by the CRU PRC. Industry-sponsored and approved and funded protocols that have been peer-reviewed externally (for example, NIH awards) received expedited review by ICTS staff. Protocols that have not been peer-reviewed or not industry-sponsored are reviewed by a member of the CRU PRC and by an external reviewer (generally a UI faculty member). All protocols are then considered for final approval at monthly meetings of the CRU PRC.
Edward Bell, MD
Michael Bosch, RN, BSN
Leon Burmeister, MS, PhD
Cathy Chenard, MS, RD, LD
Larry Fleckenstein, PharmD
Vickie Guzman, MSN, ARNP
Joel Kline, MD
Mary McDermott
Jose Morcuende, MD, PhD
D.J. Murry, PharmD
Thomas O’Dorisio, MD
Charles Rebouche, PhD
Margo Schilling, MD
William Sivitz, MD
Clark Stanford, DDS, PhD
James Wefel, PhD
John Widness, MD
Jerome Yankowitz, MD
